[Basel, Geneva – 27 September 2018]
GARDP and Novartis are joining forces to accelerate the development and availability of generic antibiotic treatments for children in low- and middle-income countries. The strategic partnership responds to the call from the World Health Organization for affordable, improved, and adapted antibiotic formulations and regimens for this vulnerable population, for which treatment options are limited.
[New Delhi/Geneva – 3 July 2018]
Study aims to guide development of new treatments and reverse global increase in deaths of newborns
Over 80 researchers from 11 countries are meeting in New Delhi today to kick off an observational study to understand sepsis in newborns and current antibiotic prescribing practices. The observational study, led by GARDP, is benefiting from US$2 million funding from Bill & Melinda Gates Foundation.
Presentation of GARDP by Dr Manica Balasegaram, Executive Director
Register for upcoming webinars on antimicrobial drug development and catch-up on those you may have missed
REVIVE is an online space for the antimicrobial R&D community to educate, connect, and share good practice in how to conduct antimicrobial drug R&D. It facilitates exchanges between clinical and non-clinical researchers with world-class experts active in antimicrobial R&D over the last 40 years. So far, more than 100 experts have engaged with REVIVE.